Skip to content
9.11 USD 0.89% +0.08
OPEN 9.06
DAY RANGE 9.18 - 9.03
52 WEEK RANGE 12.40 - 8.42
Interactive Brokers Logotype

Buy VTRS stocks now with Interactive Brokers – the most advanced investment platform

Valuations metrics

Market capitalization 10.9B
Enterprise value 29.4B
Trailing pe 5.8025475
Forward pe 3.1631942
Peg ratio 3.1631942
Price to sales ttm 0.691335
Price to book mrq 0.52191347
Enterprise to revenue 1.859
Enterprise to ebitda 5.484


Fiscal year ends 2022-12-31
Most recent quarter 2022-12-31
Profit margin 0.12051
Operating margin 0.15866
Return on assets ttm 0.0305
Return on equity ttm 0.09204
Income statement
Revenue ttm 15.8B
Revenue per share ttm 13.057
Quarterly revenue growth -0.11
Gross profit ttm 7B
Ebitda 3.4B
Net income to common ttm 1.9B
Diluted eps ttm 1.57
Quarterly earnings growth yoy -0.437
Balance sheet
Total cash mrq 587.6M
Total cash per share mrq 0.49
Total debt mrq 19B
Total debt to equity mrq 90.935
Current ratio mrq 1.577
Book value per share mrq 17.455
Cash flow
Operating cash flow ttm 2.8B
Levered free cash flow ttm 4.6B

Stock statistics

Shares outstanding 1.2B
Float shares 1.2B
Avg 10 volume 8.6M
Avg 30 volume 9.2M
Shares short 21.1M
Short ratio 2.25
Short percent of shares outstanding 0.0202
Percent held by insiders 0.0028
Percent held by institutions 0.79186994

Stock price summary

Fifty two week low 8.42
Fifty two week high 12.4
Fifty two week change -34.687
Beta 1.17558
Day 50 ma 9.473
Day 200 ma 10.3243

Dividends and splits

Forward annual dividend rate 0.48
Forward annual dividend yield 0.053200003
Trailing annual dividend rate 0.48
Trailing annual dividend yield 0.053156145
Payout ratio 0.3057
Dividend date 2023-06-16
Ex dividend date 2023-05-23
Last split factor 3-for-2 split
Last split date 2003-10-09

Viatris (VTRS) company profile

Viatris Inc. (NASDAQ: VTRS) is a healthcare company that develops, licenses, manufactures, markets, and distributes generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients. Some of the company’s popular markets include the Developed Markets, Greater China, JANZ, and Emerging Markets segments. The company’s drugs focus on infectious diseases and non-communicable diseases.